Hanall Biopharma Co., Ltd.
009420.KS
Updated: 24/09/2026, 05:06:51
HANALL BIOPHARMA Co., Ltd. engages in the manufacture and sale of synthetic drug and biopharmaceuticals. It offers products such as medicine for digestion, high blood pressure, cerebrovascular disease, myocardial infarction, anti-diabetics, antibiotics, gastrointestinal, bone structure, erectile dysfunction, hives, and other pharmaceutical products. The company was founded by Byeong-Tae Kim on November 20, 1973 and is headquartered in Daejeon, South Korea.
No summaries found.
- Share price
- ₩46,600
- Market cap
- ₩2.37T
- Exchange
- KSC
- Currency
- KRW
- CEO
- Su-Jin Park
- Employees
- 315
- IPO date
- 04/01/2000
- Beta
- 0.882
- Last dividend
- ₩0
- Day range
- ₩46,200 – ₩48,000
- 52-week range
- ₩30,400 – ₩73,000
- 1-day performance
- 1.41%
- 1-year performance
- 53.29%
- Current drawdown (1Y)
- -36.16%
- CIK
- N/A
- CUSIP
- N/A
- ISIN
- KR7009420001
- Created
- 07/09/2026, 05:16:01
- Last update
- 24/09/2026, 05:06:51
Track Hanall Biopharma Co., Ltd. with an AI analyst
See which prediction-market events move 009420.KS, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
No news found for this symbol.